Navigation Links
VIVUS to Present at Two Upcoming Investor Conferences
Date:3/3/2010

MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, Chief Financial Officer, will present an overview of the company at two investment conferences during the month of March.

    The conference presentation schedule is as follows:

     Cowen and Company 30th Annual Health Care Conference
     March 10, 2010 at 9:30 a.m. ET
     The Boston Marriott Copley Place, Boston, MA

     Roth Capital Partners 22nd Annual OC Growth Stock
      Conference
     March 16, 2010 at 12:00 p.m. PT
     The Ritz Carlton, Dana Point, CA

A live audio webcast and 30-day archive of the presentations will be available on VIVUS' website at http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next- generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.
    Timothy E. Morris
    Chief Financial Officer
    650-934-5200

    Investor Relations:
    The Trout Group
    Brian Korb
    646-378-2923

    Media Relations:
    Pure Communications, Inc.
    Dan Budwick
    973-271-6085

SOURCE VIVUS, Inc.

Back to top

RELATED LINKS
http://www.vivus.com

'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
2. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
3. VIVUS to Present at Four Upcoming Healthcare Conferences
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at the Needham and Company Life Sciences Conference
6. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
7. VIVUS Reports First Quarter 2009 Financial Results and Highlights
8. PDI to Present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference
9. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
10. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Creating a Better Health Ecosystem Focus of Presentation by Aleres Dr. Gordon Norman at Population Health & Disease Management Colloquium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):